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with human intestinal pathogens invasion
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Abstract 
Background: One of the working mechanisms of probiotic bacteria is their ability to compete with pathogens. To 
define the probiotic properties of seven Lactic Acid Bacteria (LAB) strains, we tested them for survival in simulated 
gastro-intestinal conditions, antimicrobial activities, co-aggregative abilities, and interferences studies against five 
human intestinal pathogens (Salmonella enteritidis ATCC 13076, Listeria monocytogenes ATCC 7644, Escherichia coli 
O157: H7 ATCC 35150, Cronobacter sakazakii ATCC 29544 and Campylobacter jejuni ATCC 33291).
Results: The LAB strains were able to survive the stomach simulated conditions, and varied in their abilities to sur-
vive the small intestinal-simulated conditions. The strains showed antibiotic susceptibility profiles with values equal 
or below the breakpoints set by the European Food and Safety Authority. The LAB cell-free cultures supernatants 
showed antimicrobial activities, with inhibition zones ranging from 10.0 to 17.2 mm. All the LAB strains showed mod-
erate auto-aggregation abilities while the greatest co-aggregation abilities were observed for Bifidobacterium bifidum 
W23, Lactobacillus plantarum W21 and Lactobacillus rhamnosus W71. The individual LAB strains showed strain-specific 
abilities to reduce the invasion of intestinal pathogens in an interference model with Caco-2 cells. Increased invasion 
inhibition was found when different combinations of LAB strains were used in the interference tests.
Conclusion: The LAB strains examined in this study may protect the intestinal epithelium through a series of barriers 
(antimicrobial activity, co-aggregation with pathogens, adherence) and interference mechanisms. Consequently, 
these LAB strains may be considered candidates for prophylactic use to prevent intestinal infections.
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Background
The infectious diseases caused by food-borne pathogens 
are a serious public health threat as reported by Centers 
for Disease Control and Prevention (CDC) and Food-
borne Diseases Active Surveillance Network (FoodNet) 
[1]. Food spoilage-inducing bacterial pathogens such as 
Escherichia coli O157: H7 (EHEC), Salmonella, Listeria 
monocytogenes, and Campylobacter cause numerous ill-
nesses and deaths, and huge economical loss [2]. Diar-
rhea, often caused by these pathogens, is the second 
leading cause of death in children under 5 years old and 
kills over 2 million people overall, per year [3]. Whereas 
most of the deaths occur in developing countries, also in 
developed countries a lot of foodborne and waterborne 
infectious illnesses occur, with up to 1 in 6 of Americans 
affected yearly [4]. Treatment is mainly done by oral rehy-
dration solution and anti-motility agents like loperamide 
are used widely [4]. Commonly used synthetic antibiotics 
are efficient in limiting the growth of food-borne patho-
gens, but a growing numbers of antibiotic-resistance 
among those human pathogens have been documented 
[5].
Probiotic bacteria represent a potential alternative in 
the prevention and control of food-borne infections, since 
they have proven effectiveness in reversing the patho-
genicity of food-borne pathogens. Probiotics are defined 
as live microorganisms that confer a health benefit on 
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the host when administered in adequate amounts [6, 
7]. Strains of lactic acid bacteria (LAB) belonging to the 
genera Lactobacillus and Bifidobacterium are commonly 
used as probiotics [8]. The mechanisms underlying the 
activity of LAB strains against bacterial pathogens appear 
to be multifactorial and include the production of hydro-
gen peroxide, lactic acid, bacteriocin-like molecules, 
stimulation of the immune system, and modulation of 
intestinal microbiota [9–11]. Moreover, LAB can prevent 
the adhesion of pathogens by competing for the binding 
sites on the intestinal epithelial cells and consequently, 
reduce the colonization, thereby preventing the onset of 
infection [12–14]. In order to extent beneficial effects, 
probiotics need to achieve in the intestine an adequate 
biomass through growth, biofilm formation or aggrega-
tion and, consequently, the ability to aggregate is a desira-
ble property for probiotics. In addition, micro-organisms 
with the ability to co-aggregate with other bacteria, such 
as pathogens, may have an advantage over the non-co-
aggregating bacteria that are easily removed from the 
intestinal gut [15].
Dietary intervention through food or food supplements 
containing live microbes with the aforementioned prop-
erties could be a possible step to improve the intestinal 
health status of people and to prevent infectious diar-
rhoea caused by food-borne pathogens. However, it is 
well-known that different bacterial strains of the same 
genus and species may exert completely different effects 
on the host [16]. Therefore, the specific properties of 
individual strains should be well-defined and the effect 
on health of each strain should be demonstrated in a 
case-by-case manner.
For these reasons, the potential probiotic properties 
of different LAB strains against Salmonella enteritidis 
ATCC 13076, L. monocytogenes ATCC 7644, E. coli O157: 
H7 ATCC 35150, Cronobacter sakazakii ATCC 29544 
and Campylobacter jejuni ATCC 33291 were determined 
in this study. The experimental design was subdivided in 
two distinct phases in order to: (i) determine the strain-
specific probiotic properties of the different LAB, evalu-
ating their antimicrobial activity as well as auto- and 
co-aggregation properties; (ii) study the interference of 
selected LAB strains and their combinations against the 
invasion ability of human intestinal pathogens.
Methods
Bacterial strains and culture conditions
Seven strains of lactic acid bacteria (from the probiotic 
formulation WincloveTravel), kindly provided by Win-
clove Probiotics (The Netherlands), were used in this 
study: Bifidobacterium bifidum W23 (DSM 26331), Lac-
tobacillus salivarius W24 (DSM 26403), Lactobacillus 
acidophilus W37 (DSM 26412), Lactobacillus casei W56 
(DSM 26388), Lactococcus lactis W58 (DSM 26390), Lac-
tobacillus plantarum W21 (DSM 26401) and Lactoba-
cillus rhamnosus W71 (DSM 26396). These seven lactic 
acid strains are deposited at the DSMZ culture collection. 
They have been identified based on the highest match of a 
partial DNA sequence of the small subunit (16S) riboso-
mal RNA gene of the tested strain with the sequences of 
different LAB species, in the database of the Ribosomal 
Database Project II (RDP release 9.56), or based on rep-
PCR fingerprint profile similarity to a reference culture 
that was identified as such based on the highest match of 
a partial DNA sequence of the small subunit (16S) Ribo-
somal RNA gene of the tested strain with the sequence 
of different LAB species in the database of the Ribosomal 
Database Project II (RDP release 9.56).
All the probiotic strains were grown on Man Rogosa 
Sharpe agar (MRS, Oxoid, Milan, Italy) for 24–48  h at 
37  °C under microaerophilic conditions (5% O2; 10% 
CO2, 85% N2); B. bifidum W23 was grown in MRS with 
the addition of 0.05% cysteine in the same culture con-
ditions. For interference studies, five reference human 
intestinal pathogens S. enteritidis ATCC 13076, L. mono-
cytogenes ATCC 7644, E. coli O157: H7 ATCC 35150, C. 
sakazakii ATCC 29544 and C. jejuni ATCC 33291, were 
included. All pathogenic strains were grown in Tryptic 
Soy agar (TSA, Oxoid) at 37 °C for 24 h, while C. jejuni 
ATCC 33291 was grown on Columbia Agar Base (Oxoid) 
with 5% Laked Horse Blood (Oxoid) and Campylobac-
ter Growth supplement (Oxoid) at 37  °C for 48 h under 
microaerophilic conditions. All lactic acid bacteria and 
pathogenic strains were stored at −80  °C in Nutrient 
Broth No. 2 (Oxoid) with 20% of glycerol.
pH and bile tolerance tests
The survival of the lactic acid bacteria to simulated gas-
tro-intestinal (GI) tract conditions was investigated as 
described previously [17]. Briefly, each lyophilized strain 
(2 g, 109 CFU/gr) was rehydrated in 100 ml of demineral-
ized water for 15  min at room temperature. The rest of 
the experiment was performed at 37  °C in a water bath. 
The stomach was simulated by adding 1  ml of porcine 
pepsin solution (7 mg/ml porcine gastric mucosa p7000, 
Sigma) and decreasing the pH in four steps of 15  min 
to 4.8, 4.5, 3.5 and 2.5. After 75 min, the entry into the 
proximal duodenum was mimicked by increasing the pH 
to 6.5 by adding 0.1 N NaOH and, after 90 min, 10 ml of 
porcine bile extract solution (80  mg/ml of bile extract, 
Sigma) and 2 ml of porcine pancreatin solution (50 mg/
ml pancreatin, Sigma) were added. After 3  h, bile salts 
were deactivated by adding 11.5 mM of calcium chloride. 
The pH was maintained at 6.5 until 6  h, which was the 
end of the experiment. Samples for the total cell count 
analysis were taken at the different time points, diluted in 
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phosphate buffered saline and plated in several dilutions 
on MRS agar plates. Plates were incubated for 48–72 h at 
37 °C and thereafter the colony forming units (CFU/ml) 
were counted. The experiments have been performed in 
triplicate.
Antibiotic susceptibility testing
The antibiotic resistance for all the LAB strains used 
in this study was checked by the broth micro dilutions 
method. The bacteria were tested for resistance against 
ampicillin, vancomycin, gentamycin, kanamycin, strepto-
mycin, erythromycin, clindamycin, tetracycline and chlo-
ramphenicol (VetMIC Lact-1 and 2 micro-dilution plates). 
The bacteria were plated onto MRS agar plates and grown 
for 24–48 h. A single colony of each strain was diluted in 
saline solution (McFarland 0.5) and distributed over 96 
wells microtiter plates with LAB susceptibility medium 
[18] and different concentrations of antibiotics with a final 
bacterial load of 105 CFU/ml. The plates were incubated 
at 37 °C for 24 h. The Minimal Inhibitory Concentration 
(MIC) was determined as the lowest concentration of a 
given antibiotic at which no growth of the tested organ-
ism was observed and compared with the breakpoints set 
by the European Safety and Food Authority [19].
Preparation of pathogen strain inoculums
Pathogen strains represented by S. enteritidis ATCC 
13076, L. monocytogenes ATCC 7644, E. coli O157: H7 
ATCC 35150, C. sakazakii ATCC 29544 were grown in 
Tryptic Soy Broth (TSB) (Oxoid) at 37 °C for 24 h, while 
C. jejuni ATCC 33291 was grown in Mueller–Hinton 
Broth (MHB) (Oxoid) supplemented with 5% of Fetal 
Calf Serum (FCS) (Sigma) with gentle shaking (120 rpm) 
at 37  °C for 48  h under microaerophilic conditions. At 
the end of the incubation period, for each experiment, 
the bacterial cultures were centrifuged at 3500  rpm for 
15 min, resuspended in the adequate culture media and 
adjusted to a turbidity of about 108 CFU/ml by spectro-
photometer reader using OD660 for C. jejuni ATCC 33291 
and OD610 for all the other intestinal pathogens [20, 21].
Antimicrobial activity of LAB “cell‑free cultures 
supernatants”
For the “cell-free cultures supernatant” (CFCS) extrac-
tion, the lactic acid bacteria were inoculated into 100 ml 
of MRS broth at 37  °C for 48  h under microaerophilic 
conditions. The obtained cultures were centrifuged at 
12,000  rpm for 15  min at 4  °C and the supernatants 
(CFCSs), adjusted to pH 6.5, were filtered with pore size 
0.22 µm membranes and stored at −20 °C until use.
The antibacterial properties of the CFCSs was deter-
mined using the agar well diffusion method (AWDM). 
Briefly, the pathogenic strains were grown overnight in 
TSB at 37 °C and then 500 µl of each culture (107 CFU/
ml) were added to 25  ml of Nutrient Agar. The plates 
were let solidify at room temperature for 20  min; sub-
sequently, on their surface, 6 mm holes were aseptically 
created. Finally, each well was filled with 50  µl of the 
different CFCSs and the plates were incubated at 37  °C 
for 24  h. After incubation, the zones of growth inhibi-
tion around each well, considered index of antimicrobial 
activity of the CFCSs, were measured and registered. 
Each experiment was performed in triplicate.
Aggregative abilities of LAB strains
Auto-aggregation and co-aggregation abilities of each 
LAB strain were evaluated. For auto-aggregation ability, 
LAB strains were grown in MRS broth at 37 °C for 24 h 
under microaerophilic conditions, as described above. 
Then, the bacterial cultures were centrifuged at 3500 rpm 
for 10 min and the bacteria were resuspended in 10 ml of 
PBS to approximately 108 CFU/ml (OD550 0.2–0.3). Each 
suspension was vortexed for 10 s and incubated for 6 h at 
room temperature. At each hour, 1 ml of the upper part of 
each suspension was withdrawn to measure the absorb-
ance at 600 nm. The percentage of auto-aggregation was 
then calculated according to the following formula:
where At is the absorbance at different time points and 
A0 the initial one.
For co-aggregation abilities, 2-ml aliquots of pairs of 
bacterial suspensions (probiotic and pathogen) were 
vortexed for 10  s. Samples containing 4-ml aliquots of 
a single bacterial suspension were used as control. Each 
suspension was vortexed for 10  s and incubated for 6 h 
at room temperature. At each hour, 1  ml of the upper 
part of each suspension was withdrawn to measure the 
absorbance as described above. The co-aggregation per-
centages were finally calculated as follow:
where Ax and Ay are the individual aggregation properties 
of the lactobacilli and the pathogen, and A(x + y) is the 
combined aggregation of the lactobacilli and the patho-
gen. All the experiments were performed in duplicate.
Cell cultures
Caco-2 cells, human colon carcinoma cells, were grown 
routinely in 25  cm2 flasks containing approximately 
6  ml of D-MEM (Sigma) supplemented with 10% Fetal 
Calf Serum (FCS) (Sigma), 1% of non-essential amino 
acids (Sigma) and 1% of antibiotics (penicillin and 
streptomycin) (Sigma) at 37 °C with 5% CO2. For all the 
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experiments, Caco-2 cells were treated with trypsin, 
seeded at a ratio of 2 × 104 cells/ml in 6-well plates and 
used as differentiated cells after 15 days in culture. Before 
the assays, the cell monolayers were washed twice with 
phosphate buffered saline (PBS) pH 7.2
Adhesive properties of LAB strains on Caco‑2 cells
The adhesive properties of LAB strains were evaluated on 
Caco-2 monolayers prepared as described above. Briefly, 
a loopful of each LAB strain was transferred into a ster-
ile glass tube containing 10 ml of MRS broth; for B. bifi-
dum W23 was used MRS broth with 0.05% of cystein. 
All tubes were then incubated at 37  °C for 24  h under 
microaerophilic conditions. At the end of incubation, 
the bacterial cultures were centrifuged at 3500  rpm for 
10  min and resuspended in D-MEM with 1% FCS. The 
bacterial density of each culture was adjusted to OD600 
of 0.9–1 corresponding to about 108 CFU/ml. These sus-
pensions were co-incubated with Caco-2 monolayers 
for 1 h at 37 °C in 5% CO2. After the incubation period, 
supernatants were discarded and the monolayers were 
softly washed twice with phosphate saline buffer (PBS) 
to remove the non-attached bacteria. The monolayers 
were finally trypsinized to release the eukaryotic cells 
and adhered bacteria; after appropriate serial dilutions 
in physiological saline solution, the number of adhered 
bacteria was enumerated on MRS agar after incubation 
at 37 °C for 24 h under microerophilic conditions. Results 
were expressed as the percentage of bacteria adhered 
with respect to the amount of bacteria added (% CFU 
bacteria adhered/CFU bacteria added) [15].
Invasion inhibition by interference studies with selected 
LAB strains and their combinations
Interference assays were carried out using B. bifidum W23, 
L. salivarius W24 and L. rhamnosus W71; each selected on 
the basis of their adhesive and aggregative abilities. Exclu-
sion and competition tests were used as infection schemes 
on Caco-2 cell monolayers with specific time of infection 
for each pathogen: 2 h for S. enteritidis ATCC 13076 and L. 
monocytogenes ATCC 7644, 3 h for E. coli O157: H7 ATCC 
35150 and C. sakazakii ATCC 29544, 4  h for C. jejuni 
ATCC 33291. The bacterial suspensions of LAB and patho-
gen strains were prepared as described above.
For the exclusion test, Caco-2 monolayers were 
infected with 1  ml of each LAB suspension for 1  h and 
then washed with PBS to remove non-adherent bacte-
ria; at this point, 1 ml of each pathogenic suspension was 
added to cells monolayers for the appropriate incuba-
tion time at 37 °C with 5% of CO2. At the end of incuba-
tion, cells were washed 3–5 times with PBS, treated with 
D-MEM gentamicin solution (250  µg/ml) for 2  h and 
lysed with Triton X-100 (0.5% in PBS). Finally, cell lysates 
were serially diluted in physiological saline solution, 
plated on the adequate agar and incubated in the appro-
priate culture condition for the CFU/ml enumeration.
For the competition test, cells were exposed to a mixed 
suspension (1:1) of each pathogen with each LAB strain. 
After the appropriate incubation times at 37 °C with 5% 
of CO2, monolayers were washed 3–5 times with PBS, 
treated with D-MEM gentamicin solution (250  µg/ml), 
washed with PBS, and lysed with Triton X-100 (0.5% in 
PBS). The lysates were then serially-diluted in saline, and 
plated on the adequate agar and incubated in the culture 
condition for CFU/ml enumeration.
Subsequently, for each pathogen, the exclusion and 
competition exposure schemes were performed using the 
four following LAB strains combinations:
i. B. bifidum W23 + L. salivarius W24
ii. B. bifidum W23 + L. rhamnosus W71
iii. L. salivarius W24 + L. rhamnosus W71
iv. B. bifidum W23 + L. salivarius W24 + L. rhamnosus 
W71
The interference studies were performed as described 
above with the difference that Caco-2 cells were infected 
with pathogens and each LAB combination. Infection on 
Caco-2 cells, gentamicin killing protection assay, cellu-
lar lysis and viable counts were carried out as previously 
described.
All the interference assays were performed in duplicate.
Statistical analysis
Statistical analysis was performed using Prism 5.0 (Graph-
Pad Software, Inc., La Jolla, USA). The conditions necessary 
to perform parametric tests were checked before conduct-
ing the analysis, otherwise non-parametric tests were uti-
lized. The level of significance was considered α = 0.05.
Results
Strain‑specific probiotic properties
The in vitro GI survival data for the seven LAB strains are 
shown in Fig. 1. All the strains showed good survival to 
the simulated stomach conditions. In particular, L. aci-
dophilus W37 showed a reduction of approximately one 
log CFU/ml, while the other strains had a much lower 
reduction of CFU/ml. The ability to survive to the simu-
lated conditions of the small intestinal differed between 
the strains. In detail, L. acidophilus W37, L. rhamnosus 
W71, and L. salivarius W24 were unable to survive in 
this in  vitro GI model, while L. casei W56 and L. lactis 
W58 showed a reduction of 3 log CFU/ml, and L. plan-
tarum W21 of 1.5 log CFU/ml. Finally, B. bifidum W23 
showed only a twofold reduction of CFU/ml value at the 
end of the experiment (Fig. 1).
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The minimal inhibitory concentrations of nine different 
antibiotics for the seven LAB strains are summarized in 
Table 1; all values are equal or below the breakpoints set 
by the European Food and Safety Authority.
Antimicrobial activity of CFCSs against food‑borne 
pathogens
The antimicrobial effect of CFCSs extracted from each 
LAB strain against selected food-borne pathogens 
are summarized in Table  2. The CFCSs tested in this 
experiment were able to inhibit the growth of intestinal 
pathogens with a variable degree of antibacterial activity. 
In fact, the CFCSs of L. lactis W58, L. plantarum W21, 
and L. rhamnosus W71 showed a wide antimicrobial 
activity against all the food-borne pathogens included in 
this study, whilst the others CFCSs have demonstrated a 
limited or absent antimicrobial activity.
Specifically, the greatest zones of growth inhibition, 
17.2  ±  0.21 and 17.1  ±  0.21  mm, were reached by the 
CFCS of L. rhamnosus W71 and L. casei W56 toward 
C. jejuni ATCC 33291, the microorganism resulted 

































































Fig. 1 In vitro GI survival data of LAB strains. Each lyophilized strain (2 g, 109 CFU/gr) was rehydrated in 100 ml of demineralized water for 15 min 
at room temperature (baseline). The rest of the experiment was performed at 37 °C. The stomach was simulated by adding 1 ml of porcine pepsine 
solution and decreasing the pH in four steps of 15 min to 4.8, 4.5, 3.5 and 2.5. After 75 min (stomach), the entry into the proximal duodenum was 
mimicked by increasing the pH to 6.5 by adding 0.1 N NaOH and, after 90 min, 10 ml of porcine bile extract solution and 2 ml of porcine pancreatin 
solution were added. After 3 h (duodenum), bile salts were deactivated by adding 11.5 mM of calcium chloride. The pH was maintained at 6.5 until 
6 h (ileum) which was the end of the experiment. The experiments have been performed in triplicate
Table 1 Minimum inhibitory concentrations (MIC, mg/l) of the tested LAB strains for nine different antibiotics
In square brackets are indicated the microbial breakpoint according to the European Food and Safety Authority [19]. Strains with MICs higher that the breakpoint are 
considered resistant
Amp ampicillin, Van vancomycin, Gen gentamycin, Kan kanamycin, Strep streptomycin, Ery erythromycin, Clin clindamycin, Tetra tetracycline, Chlo chloramphenicol, 
n.r. not required
Amp Van Gen Kan Strep Ery Clin Tetra Chlo
B. bifidum W23 0.06 [2] 1 [2] 64 [64] n.r. 32 [128] 0.25 [1] 0.12 [1] 2 [8] 2 [4]
L. acidophilus W37 0.094 [1] 0.5 [2] 1 [16] 32 [64] 3 [16] 0.016 [1] 0.094 [1] 0.38 [4] 1.5 [4]
L. casei W56 0.5 [4] n.r. 4 [32] 64 [64] 32 [64] 0.25 [1] 0.12 [1] 2 [4] 8 [4]
L. plantarum W21 0.5 [2] n.r. 8 [16] 64 [64] n.r. 0.5 [1] 2 [2] 32 [32] 4 [8]
L. rhamnosus W71 4 [4] n.r. 2 [16] 32 [64] 8 [32] 0.12 [1] 0.5 [1] 1 [8] 4 [4]
L. salivarius W24 1 [4] n.r. 2 [16] 64 [64] 32 [64] 0.25 [1] 0.25 [1] 4 [8] 4 [4]
L. lactis W58 0.25 [2] 0.25 [4] 2 [32] 8 [64] 16 [32] 0.12 [1] 0.12 [1] 1 [4] 4 [8]
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of CFCSs against the others four food-borne pathogens 
showed lower zones of growth inhibition.
Aggregation abilities and adhesiveness of LAB strains
The auto- and co-aggregation abilities of the LAB strains 
are summarized in Table 3. After 6 h of incubation, the 
highest percentages of aggregation were seen for B. bifi-
dum W23 and L. rhamnosus W71 (21.37 and 21.08% 
respectively). All the LAB demonstrated auto-aggrega-
tion ability higher than those showed by intestinal patho-
gens, whose percentage values ranging from a minimum 
of 10.30% for E. coli O157: H7 ATCC 35150 to a maxi-
mum of 12.90% for S. enteritidis ATCC 13076. Regarding 
the co-aggregation abilities, the LAB strains that showed 
the strongest co-aggregation after 6 h of incubation were 
B. bifidum W23, L. plantarum W21 and L. rhamnosus 
W71. Specifically, B. bifidum W23 showed the highest co-
aggregation ability with C. jejuni ATCC 33291 (18.14%), 
L. plantarum W21 with S. enteritidis ATCC 13076 
(16.79%), and L. rhamnosus W71 with E. coli O157: H7 
ATCC 35150 (17.41%). All the probiotic strains were able 
to co-aggregate with C. jejuni ATCC 33291, except L. aci-
dophilus W37 and L. lactis W58 (4.33 and 3.42%).
The adhesion abilities of each LAB strain on Caco-2 
cell monolayers are represented in Fig. 2. In general, the 
examined LAB presented good adhesion ability to intes-
tinal cells with strain-specific characteristics. More spe-
cifically, B. bifidum W23 showed the highest adhesion 
index (% CFU bacteria adhered/CFU bacteria added) of 
51%, while the others strains evidenced adhesion indexes 
ranging from 25% for L. salivarius W24 to 9.5% for L. 
rhamnosus W71.
Interference of LAB strains on intestinal pathogens 
invasion ability
The capacity of B. bifidum W23, L. salivarius W24, and 
L. rhamnosus W71 to inhibit the intestinal food-borne 
pathogens invasion on Caco-2 cells, selected on the basis 
of their adhesion index and aggregative abilities, was 
determined using exclusion and competition tests. The 
interference studies against each intestinal pathogen were 
performed using LAB strains singularly and four different 
Table 2 Antimicrobial activity of the cell-free supernatants (CFCSs) produced by the different LAB strains toward human 
intestinal pathogens strains performed by agar well diffusion method
Gen gentamicin 10 µg, W trimethoprim 5 µg, Strep streptomycin 10 µg, – no visible growth inhibition











B. bifidum W23 – 10.1 ± 0.25 11.0 ± 0.35 12.1 ± 0.25 12.1 ± 0.32
L. salivarius W24 10.1 ± 0.32 – – 10.2 ± 0.11 10.1 ± 0.28
L. acidophilus W37 – 11.1 ± 0.12 – – 12.1 ± 0.36
L. casei W56 – 11.1 ± 0.51 – 10.2 ± 0.21 17.1 ± 0.21
L. lactis W58 11.0 ± 0.15 11.0 ± 0.27 12.0 ± 0.28 11.1 ± 0.15 10.5 ± 0.51
L. plantarum W21 10.1 ± 0.31 14.1 ± 0.34 10.0 ± 0.20 10.1 ± 0.28 13.5 ± 0.52
L. rhamnosus W71 10.1 ± 0.24 12.1 ± 0.31 11.0 ± 0.15 10.2 ± 0.25 17.2 ± 0.21
Positive control 16.3 ± 0.53 (Gen) 19.3 ± 0.63 (W) 15.6 ± 0.64 (Gen) 16.3 ± 0.52 (Strep) 32 ± 0.51 (Gen)
Table 3 Percentages of auto- and co-aggregation abilities of the different LAB strains with intestinal pathogens












B. bifidum W23 21.37 (±1.12) 14.86 (±0.28) 11.96 (±0.20) 10.27 (±0.31) 10.07 (±0.28) 18.14 (±1.02)
L. salivarius W24 19.33 (±1.81) 6.82 (±0.20) 8.33 (±0.12) 10.31 (±0.21) 7.06 (±0.22) 15.84 (±0.32)
L. acidophilus W37 15.90 (±1.20) 14.2 (±0.19) 8.35 (±0.11) 3.85 (±0.01) 9.52 (±0.19) 4.33 (±0.02)
L. casei W56 15.92 (±1.72) 6.34 (±0.11) 5.14 (±0.15) 5.64 (±0.14) 5.34 (±0.11) 13.94 (±0.32)
L. lactis W58 15.50 (±1.21) 13.94 (±0.31) 7.13 (±0.13) 9.32 (±0.21) 4.54 (±0.31) 3.42 (±0.28)
L. plantarum W21 15.03 (±1.61) 16.79 (±0.35) 14.62 (±0.31) 12.01 (±0.24) 4.72 (±0.34) 13.00 (±0.21)
L. rhamnosus W71 21.08 (±1.83) 15.93 (±0.24) 13.73 (±0.22) 17.4 (±0.22) 12.51 (±0.26) 11.00 (±0.23)
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combinations of LAB strains as described in “Methods” 
section.
As a general trend, each tested LAB strain was able 
to inhibit the invasiveness of S. enteritidis ATCC 13076, 
L. monocytogenes ATCC 7644, E. coli O157: H7 ATCC 
35150, C. sakazakii ATCC 29544 and C. jejuni ATCC 
33291 with a variable degree dependent on the bacterial 
species (Fig. 3). Each single LAB strain showed weak abil-
ity to reduce the invasion of S. enteritidis ATCC 13076 on 
Caco-2 cells. The LAB combinations provoked a higher 
decrease of internalized S. enteritidis ATCC 13076 in 
both the interference tests (Fig. 3a).
The three single LAB strains demonstrated good inter-
ference activity against the invasion ability of L. monocy-
togenes ATCC 7644 (Fig. 3b), with a remarkable decrease 
of recovered internalized bacteria after gentamicin pro-
tection assay on Caco-2 cell monolayers. Statistically sig-
nificant (p value <0.05) reductions of L. monocytogenes 
ATCC 7644 numbers were registered in the interference 
tests with all the four LAB combinations.
The tested LAB strains were also able inhibit the inva-
sion ability of E. coli O157: H7 ATCC 35150 (Fig.  3c). 
As observed for the others tested intestinal pathogens, 
the four LAB combinations induced a more remark-
able decrease of the internalized E. coli O157: H7 ATCC 
35150 in comparison with the individual strains. The sin-
gle LAB strains were able to weakly interfere with Caco-2 
invasion ability of C. sakazakii ATCC 29544 (Fig. 3d), and 
4.48 log CFU/ml, a statistically significant decrease of the 
recovered internalized bacteria, was registered only in 
the exclusion test performed with L. rhamnosus W71, 
compared to 5.30 log CFU/ml of the control internalized 
C. sakazakii ATCC 29544. In the interference studies car-
ried out with the four LAB combinations, the most con-
siderable decrease of the internalized C. sakazakii ATCC 
29544 (4.75 log CFU/ml) was obtained in the exclusion 
tests with the combination formed by B. bifidum W23 
and L. salivarius W24 and in the competition test with 
that formed by B. bifidum W23, L. salivarius W24 and L. 
rhamnosus W71.
Finally, regarding C. jejuni ATCC 33291, the obtained 
results indicated that each single LAB strains inhibited 
the invasion ability of C. jejuni ATCC 33291 (Fig. 3e). In 
detail, statistically significant reductions of the internal-
ized C. jejuni ATCC 33291, compared to the control ones 
(6.52 log CFU/ml), were registered in the exclusion test 
with B. bifidum W23 (5.24 log CFU/ml) or L. rhamnosus 
W71 (5.01 log CFU/ml), while the lowest values of inter-
nalized C. jejuni ATCC 33291 was evidenced in the com-















Fig. 2 Adhesion ability of the different LAB strains to the human Caco-2 cell monolayers. Caco-2 monolayers were incubated for 1 h with a LAB 
strain. Thereafter the supernatants were discarded and the monolayers were washed to remove the non-attached bacteria. Then the monolayers 
were trypsinized to release the eukaryotic cells and adhered bacteria and the bacteria were plated on MRS plates. Results are expressed as the 
percentage of bacteria adhered with respect to the amount of bacteria added (% CFU bacteria adhered/CFU bacteria added). The experiments have 
been performed in triplicate
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The four LAB combinations were also able to consider-
ably reduce the number of internalized C. jejuni ATCC 
33291.
The findings for all pathogens and all tested LAB strains 
and combination are summarized in Table 4.
Discussion
Probiotic characterization of each LAB strain
The ability to survive an in vitro GI model varied between 
the tested LAB strains. Strain specific tolerance to stom-
ach acidity and/or GI survival has been shown before 
Fig. 3 Invasion inhibition of human intestinal pathogens by single LAB strains and their four combinations. a S. enteritidis ATCC 13076, b L. 
monocytogenes ATCC 7644, c E. coli O157: H7 ATCC 35150, d C. sakazakii ATCC 29544, e C. jejuni ATCC 33291. Asterisks represented values statistically 
significant (p < 0.05) in comparison to the control group (Kruskal–Wallis non parametric test)
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[17, 22, 23]. Surprisingly, the main decrease in viable was 
found in the simulated conditions of small intestinal, and 
not under the acid stomach conditions. In general most 
LAB appear to possess a natural ability to survive pan-
creatin [24, 25]. In contrast pancreatin tolerance, bile 
tolerance is strain-specific [26], so this might cause the 
observed differences is survival. In  vivo, the amount of 
bile shows high variability to time, along the length of 
the GI tract and amongst individuals, and the conditions 
in our in  vitro model might not adequately reflect the 
in vivo situation, where food matrices might help survival 
of the bacteria.
Antibiotic resistance and transferability of antibiotic 
resistance genes from probiotic strains to commensal 
microbiota in the gut are important components of the 
safety of bacteria used as probiotics [27]. No antibiotic 
resistance was found in these commercial available LAB 
strains for the EFSA panel of antibiotics, whereas this 
has been found in some other studies [28]. These latter 
results highlights the importance of antimicrobial sus-
ceptibility testing as part of the safety analysis of poten-
tial probiotic strains.
In the present study different LAB strains were evalu-
ated for their ability to antagonize human intestinal 
pathogens by secretion of antimicrobial compounds, 
interference with bacterial growth and interference 
with pathogens during adhesion/invasion process on 
epithelial cells. The antimicrobial activity of the CFCS 
of seven LAB strains against five intestinal pathogens 
was first determined by agar well diffusion method; as 
reported, two strains, L. casei W56 and L. rhamnosus 
W71, showed relative strong antibacterial activity (inhi-
bition zone >15 mm) and all the others strains moderate 
activity (inhibition zone between 10 and 15 mm) against 
the tested pathogens. As these cultured broths were neu-
tralized to pH 6.5, the inhibitory activity to pathogenic 
bacteria is probably due to production of antibacterial 
molecules rather than to the acidic conditions of the cul-
tural media. Our data are in agreement with several stud-
ies referring antimicrobial activity of LAB strains [29, 30]. 
Whether this is due to production of organic acids (e.g., 
lactic acid and acetic acid), hydrogen peroxide, bacteri-
ocins or other compounds was not investigated in our 
study.
Other important properties, linked to beneficial effects 
of probiotics, are the auto-aggregation and the co-aggre-
gation, defined as the accumulation of bacteria of the 
same species and the accumulation of bacteria of dif-
ferent species respectively. These properties are funda-
mental for probiotics since auto-aggregation seems to 
be correlated with the adherence to epithelial cells [15, 
31], a prerequisite for colonization and persistence in 
the gastrointestinal tract, while co-aggregation repre-
sents a barrier to prevent intestinal surface colonization 
of pathogenic microorganisms [32]. It has been suggested 
that cellular aggregation could be positive in promot-
ing the colonization of beneficial micro-organisms, as 
reported for lactobacilli in the gastrointestinal or vagi-
nal tract [33, 34]. In our study, the LAB strains showed 
relatively higher auto-aggregation compared to intestinal 
pathogens, suggesting that this property may allow them 
to survive at sufficiently high number and colonize the 
Table 4 Invasion inhibition of single LAB strains and their combinations against human intestinal pathogens
Strains and interference test Single LAB strains LAB combinations
W23 W24 W71 W23 + W24 W23 + W71 W24 + W71 W23 + W24 + W71
S. enteritidis ATCC 13076
 Exclusion (%) 27.92 31.82 57.14 55.19 80.52 74.68 68.83
 Competition (%) 20.13 45.45 47.40 62.99 82.47 53.25 80.52
L. monocytogenes ATCC 7644
 Exclusion (%) 76.94 90.78 86.16 97.23 95.39 97.23 95.85
 Competition (%) 90.78 90.78 95.39 97.23 99.08 98.16 98.16
E. coli O157:H7 ATCC 35150
 Exclusion (%) 88.11 77.95 66.14 93.70 93.70 92.13 93.70
 Competition (%) 65.35 49.61 52.76 94.49 78.74 85.83 77.95
C. sakazakii ATCC 29544
 Exclusion (%) 56.19 61.90 82.86 71.67 63.33 61.67 66.67
 Competition (%) 65.71 23.81 52.38 68.33 66.67 56.67 71.67
C. jejuni ATCC 33291
 Exclusion (%) 94.80 88.30 96.90 95.00 96.00 90.70 97.00
 Competition (%) 80.00 73.00 99.10 93.00 97.00 94.00 94.00
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gastrointestinal tract. All the LAB strains tested showed 
co-aggregation abilities with pathogens, with percentages 
depended on the strain (probiotic and pathogen strains) 
and time of co-incubation. All the LAB strains showed 
co-aggregation and aggregation abilities, in particular B. 
bifidum W23 and L. rhamnosus W71. Our results are in 
agreement with Collado et al. [15], who reported a cor-
relation between auto-aggregation and co-aggregation 
properties. In addition, our results suggest that the abil-
ity of LAB to promote co-aggregation with pathogens 
and to compete for adhesion to the epithelial cell surface 
is strain-dependent, probably related with the presence 
of specific molecules in the LAB surface acting either as 
ligands binding pathogens and/or as adhesins for attach-
ment to epithelial cells [35].
Since the binding to epithelial cells is valuable for pro-
biotic bacteria, we also determined the ability of our LAB 
strains to adhere to Caco-2 intestinal cells. The adhesion 
index of the tested strains showed a variability depending 
on the strain, species and genera; in fact, the most adhe-
sive strain resulted to be B. bifidum W23, while, among 
the Lactobacillus spp., the observed adhesion properties 
differs from species to species. Our data are consistent 
with studies carried out on the LAB adhesion, showing 
that this ability was strain-specific and varied within the 
same species [36–38].
Interference studies between LAB and intestinal 
pathogens
To colonize the human gastrointestinal (GI) tract, path-
ogen bacteria must compete with gut resident micro-
biota, such as lactic acid bacteria that play crucial roles 
in maintaining the microbial ecosystem of the GI by pre-
venting colonization and infection of incoming bacterial 
pathogens [8, 12–14]. It is very important to underline 
that potential probiotic strains are unique and strains of 
the same genus and species may have different beneficial 
effects [14]. In addition, it is assumed that the combina-
tions of specific probiotic strains potentiate the benefi-
cial effects to the host compared to the probiotic strains 
alone [39]. In this study, after determining the specific 
properties of individual LAB strains, three strains and 
their four combinations were selected and tested for their 
ability to inhibit the invasiveness of S. enteritidis ATCC 
13076, L. monocytogenes ATCC 7644, E. coli O157: H7 
ATCC 35150, C. sakazakii ATCC 29544 and C. jejuni 
ATCC 33291 on Caco-2 monolayers. The LAB selection 
showed the following specific probiotic properties: B. 
bifidum W23 possessed moderate auto-aggregative and 
co-aggregative abilities, high antimicrobial activity, and 
high adhesion index; L. salivarius W24 showed moderate 
auto-aggregative and weak co-aggregative abilities, high 
antimicrobial ability, and medium adhesion index; while 
L. rhamnosus W71 had high auto-aggregative and co-
aggregative abilities, moderate antimicrobial activity, and 
low adhesion index. Our data demonstrated that each 
LAB was able to reduce the invasion ability of intestinal 
pathogens; this is in agreement with other studies report-
ing the protective effect of lactic acid bacteria against Sal-
monella spp., L. monocytogenes, and C. jejuni [13, 40–42].
The ability to inhibit the invasion of intestinal patho-
gens indicates a very high strain-specificity. In fact, B. 
bifidum W23 and L. rhamnosus W71 were able to reduce 
the invasion of the tested pathogens by exclusion as well 
as by competition, while L. salivarius W24 prevalently 
appeared to operate exclusively via exclusion. Regarding 
the putative mechanisms of bacterial antagonism, co-
aggregation could be one probiotic mechanism of action 
to prevent the attachment of pathogens to the intesti-
nal surface and avoid its binding to the cellular line [13, 
43]. In our case, B. bifidum W23 and L. rhamnosus W71 
both co-aggregated well and reduced the invasion of the 
intestinal pathogens L. monocytogenes ATCC 7644 and C. 
jejuni ATCC 33291. On the contrary, L. salivarius W24 
did not appear to use co-aggregation as its mechanism of 
action to reduce the invasion of L. monocytogenes ATCC 
7644 and C. jejuni ATCC 33291. These results support 
the hypothesis that there are multiple mechanisms by 
which probiotics exert antagonistic action against intesti-
nal pathogens, and since surface components of LAB are 
implicated in adhesion, co-aggregation and bacteria–bac-
teria interactions, these phenomena could be probably 
interrelated.
According to the hypothesis that a combination of LAB 
strains may be more effective in vivo than single strains 
[7, 35], we found increased percentages of invasion inhi-
bition by the four LAB strain combinations compared to 
those of the individual LAB strains. Particularly inter-
esting is the case of S. enteritidis ATCC 13076; in fact, 
when tested against this pathogen, the individual LAB 
strains reached low percentages of invasion inhibition 
(maximum value 57.14% by L. rhamnosus W71 in the 
exclusion test), whilst the LAB combinations achieved a 
greater cumulative percentage of invasion inhibition up 
to 82.47%. Similarly, regarding C. sakazakii ATCC 29544, 
the LAB combinations have reached higher percentages 
of invasion inhibition, even whilst most cases of the sin-
gle LAB strains have gained good results (up to 82.86% of 
invasion inhibition). These findings demonstrate that the 
tested LAB combinations possess probiotic properties, 
supporting the hypothesis that the use of probiotic com-
binations, selected for their strain-specific characteris-
tics, may increase the beneficial effects on human health 
[9, 39].
To our knowledge, this is the first work where LAB 
strains were tested individually as well as in combination 
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by in  vitro interference tests with intestinal pathogens. 
To verify the ability of different LAB strains, also in their 
combinations, to inhibit the invasion of pathogenic bac-
teria appears important for the selection of new probi-
otic microorganisms. For these reasons, the tested LAB 
may be potential candidates to develop new probiotic 
combinations to prevent or treat infections by a specific 
pathogen.
Conclusions
LAB strains with good abilities to adhere to epithe-
lial cells could be better suited to colonize the intestine. 
They can act as a barrier to fight pathogens through dif-
ferent competitive mechanisms, like antimicrobial activ-
ity, co-aggregation with pathogens, and adherence. For 
this, among the tested LAB strains, B. bifidum W23, L. 
salivarius W24 and L. rhamnosus W71 have the best 
characteristics showing good antimicrobial activity as 
well as high interference activity with pathogen inva-
sion. In addition, the LAB combinations, with enhanced 
antagonizing activity against the tested intestinal patho-
gens, confirm the importance of specific probiotic com-
binations to potentiate the beneficial effects to the host 
(Additional file 1: Figure S1).
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